Metabolic syndrome in psychiatric patients: Guidelines to prevention, diagnosis and treatment;Síndrome metabólica em pacientes psiquiátricos: Orientações para prevenção, diagnóstico e tratamento

Jornal Brasileiro de Psiquiatria

Volumn 54, Issue 4, 2005, Pages 334-339

  Teixeira, Paulo J R ^a,c   Moreira, Rodrigo O ^b   Rocha, Fábio L ^a  

^a Instituto de Previdencia Dos Servidores do Estado de Minas Gerais IPSEMG   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Rua Fernandes Tourinho   (Brazil)

Author keywords

Insulin resistance; Mental disorders; Metabolic syndrome; Psychotropic drugs

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; GUANETHIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LITHIUM; METFORMIN; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NALTREXONE; NORCLOZAPINE; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PSYCHOTROPIC AGENT; RISPERIDONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

BIPOLAR DISORDER; CARDIOVASCULAR RISK; DEPRESSION; DIET; DYSLIPIDEMIA; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSULIN RESISTANCE; LIFESTYLE; MEDLINE; MENTAL PATIENT; METABOLIC SYNDROME X; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; SCHIZOPHRENIA;

EID: 33644589547     PISSN: 00472085     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Alberti KGMM, Zimmet PZ, forthe WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus. Provisional Report of a WHO Consultation. Diabet Med, 15: 539-53, 1998.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry, 65: 267-72, 2004.
3. Baptista T, Kin NY, Beaulieu S. Treatment of metabolic disturbances caused by antipsychotic drugs. Clin Pharmacokinet, 43: 1-15, 2004.
4. Basu R, Brar JS, Chengappa KNR, John V, Parepally H, Gershon S, Schlicht P, Kupfer DJ. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar disorders, 6: 314-8, 2004.
5. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavorial therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry, 66: 205-12, 2005.
6. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med, 29: 697-701, 1999.
7. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry, 177: 212-7, 2000.
8. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry, 65(suppl 18): 27-35, 2004.
9. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Semyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry, 65(suppl 7): 4-16, 2004.
10. Cohn T, Prud'homme D, Streiner D, Kamen H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of metabolic syndrome. Can J Psychiatry, 49: 753-60, 2004.
11. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic add: a retrospective study. Can J Neurol Sci, 24: 24044, 1997.
12. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry, 62: 486-91, 2001.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285: 2486-97, 2001.
14. Fava M. Weight gain and antidepressants. J Clin Psychiatry, 61(suppl 11): 37-41, 2000.
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the third national health and nutrition examination survey. JAMA, 287: 356-9, 2002.
16. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol, 8: 323-30, 1988.
17. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation, 109: 133-8, 2004.
18. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome. Report of the National Heart, Lung, and Blood Instittute/American Heart Association Conference on Scientific Issues Related to Management. Circulation, 109: 551-6, 2004.
19. Hamoui N, Kingsbury S, Anthone GJ, Crookes PF. Surgical treatment of morbid obesity in schizophrenic patients. Obesity Surgery, 14: 349-52, 2004.
20. Harris EC, Barraclough B. Excess of mortality of mental disorder. Brit J Psychiatry, 173: 11-52, 1998.
21. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry, 64: 575-9, 2003.
22. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. Adouble-blind, placebo-controlled trial of sibutramin for olanzapine-assodated weight gain. Am J Psychiatry, 162: 954-62, 2005.
23. Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain. Ann Pharmacother, 39: 302-10, 2005.
24. Holt RIG, Peveler RC, Byme CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med, 21: 515-23, 2004.
25. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Disponível em: 〈www.idf.org/webdata/ docs/ IDF_Metasyndrome_definiton.pdf〉.Acesso em: 3 jun. 2005.
26. Isojärvi JIT, Rättyä J, Myllylä W, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol, 43: 446-51, 1998.
27. Jefferson JW, Greist JH. Lithium. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Lippincott Williams & Wilkins, p. 2839-51, Philadelphia, 2005.
28. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and Non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry, 6: 74-7, 2004.
29. Kinder LS, Camethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med, 66: 316-22, 2004.
30. Le Fevre, PD. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scot Med J, 46: 11-13, 2001.
31. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, Newman MF. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med, 66: 305-15, 2004.
32. Matos AFG, Moreira RO, Guedes EP. Aspectos neuroendocrinos da sindrome metabólica. Arq Bras Endocrinol Metab, 47: 410-21, 2003.
33. McCaffery JM, Niaura R, Todard JF, Swan GE, Carmelli D. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute Twin Study. Psychosom Med, 65: 490-7, 2003.
34. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality: a general population study. Arch Gen Psychiatry, 44: 473-80, 1987.
35. Nasrallah HA, Newcomer JW. Atypical antipsychotic and metabolic dysregulation. J Clin Psychopharmacol, 24: S7-S14, 2004.
36. Ramasubbu R. Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Med Hypotheses, 59: 537-51, 2002.
37. Rosenbaum P, Ferreira SRG. An update on cardiovascular risk of metabolic syndrome. Arq Bras Endocrinol Metab, 47: 220-7, 2003.
38. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment - the metabolic syndrome. Life Sci, 71: 239-57, 2002.
39. Sociedade Brasileira de Hipertensão, Sodedade Brasileira de Cardiologia, Sociedade Brasileira de Endocrinologia e Metabologia, Sociedade Brasileira de Diabetes, Assodação Brasileira para Estudos da Obesidade. I Diretriz Brasileira de Diagnóstico e Tratamento da Sindrome Metabólica. Hipertensão, 7: 124-59, 2004.
40. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion, 6: 152-8, 2004.
41. Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry, 65(suppl 18): 13-26, 2004.
42. Writing Group of Premier Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control. JAMA, 289: 2083-93, 2003.
43. Zimmermann U, Thomas K, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res, 37: 193-220, 2003.